Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06000813 · ClinicalTrials.gov registry record · NA
REACH-Es: Adapting a Digital Health Tool to Improve Diabetes Medication Adherence Among Latino Adults
A NA study of Medication Adherence and Type 2 Diabetes (Adult Onset), sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06000813: Active NA study of Medication Adherence and Type 2 Diabetes (Adult Onset), sponsored by Massachusetts General Hospital.
NCT06000813 is a NA study of Medication Adherence and Type 2 Diabetes (Adult Onset) that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 70 participants, below the 1,655-participant average among 52 other Medication Adherence trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06000813, a NA study of Medication Adherence and Type 2 Diabetes (Adult Onset), is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Latino individuals, the fastest growing ethnic minority population in the United States, have a higher prevalence of type 2 diabetes and diabetes-related complications, and are more likely to report inconsistent use of diabetes medications than non-Hispanic White individuals. The proposed project will test an interactive text message-based tool tailored to address barriers to taking diabetes medications that are relevant to Latino adults. If found feasible, acceptable, and usable, this intervention could serve as a scalable tool to improve diabetes management and reduce diabetes-related complications among Latino adults in the United States.
Primary Outcome
Number of eligible participants who enroll/ Number of eligible participants who are contacted and reached by phone
Conditions Studied
Interventions
- BEHAVIORAL ETAU
- BEHAVIORAL REACH-Es
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Diabetes Research Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-06-18 |
| Est. Completion | 2027-02-28 |
| Phase | NA |
What the registry record for NCT06000813 still lists
NCT06000813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,655-participant average among 52 other Medication Adherence trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Medication Adherence appearing as the primary indexed condition, and to 2 interventions - of which ETAU is the first listed.
NCT06000813 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06000813 about?
NCT06000813 is a clinical study titled "REACH-Es: Adapting a Digital Health Tool to Improve Diabetes Medication Adherence Among Latino Adults". Latino individuals, the fastest growing ethnic minority population in the United States, have a higher prevalence of type 2 diabetes and diabetes-related complications, and are more likely to report inconsistent use of diabetes medications than non-Hispanic White individuals. The proposed project wi...
What is the current status of trial NCT06000813?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2024-06-18. Estimated completion is 2027-02-28.
What conditions does trial NCT06000813 study?
This clinical trial studies the following conditions: Medication Adherence, Type 2 Diabetes (Adult Onset).
What interventions are being tested in trial NCT06000813?
The interventions under investigation include: ETAU (BEHAVIORAL), REACH-Es (BEHAVIORAL).
Who is sponsoring clinical trial NCT06000813?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06000813 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medication Adherence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06000813's enrollment target sits among peer trials
70 40th of 52 higher than 11 of 52 other Medication Adherence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Medication Adherence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Medication Adherence Program
RECRUITING · NA
-
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
RECRUITING · NA
-
Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches
RECRUITING · NA
-
Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI